Enhanced anticoagulant effect of warfarin in a patient treated with cloxacillin

International Journal of Clinical Pharmacology and Therapeutics

Volumn 50, Issue 6, 2012, Pages 431-433

  Marusic, Srecko ^a   Gojo Tomic, Nives ^a   Bacic Vrca, Vesna ^a   Franic, Miljenko ^a  

^a University of Zagreb   (Croatia)

Author keywords

Cloxacillin; Coagulopathy; Interaction; Warfarin

Indexed keywords

C REACTIVE PROTEIN; CLOXACILLIN; FIBRINOGEN; NEBIVOLOL; WARFARIN;

AGED; ANTIBIOTIC THERAPY; ANTICOAGULATION; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CASE REPORT; DRUG ANTAGONISM; DRUG EFFECT; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEVER; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; PATIENT COMPLIANCE; PROTEIN BLOOD LEVEL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SUPERFICIAL THROMBOPHLEBITIS; TREATMENT DURATION; VEIN PUNCTURE;

AGED; ANTI-BACTERIAL AGENTS; ANTICOAGULANTS; CLOXACILLIN; DRUG INTERACTIONS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; WARFARIN;

EID: 84861795125     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201700     Document Type: Article

References (19)

1. Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis. 2011; 31: 326-343. doi:10.1007/s11239-011-0561-1 PubMed
2. Mannucci PM, Franchini M. Old and new anticoagulant drugs: a minireview. Ann Med. 2011; 43: 116-123. doi:10.3109/07853890.2010.539250 PubMed
3. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133 (Suppl 6): 160-198.
4. Mailloux AT, Gidal BE, Sorkness CA. Potential interaction between warfarin and dicloxacillin. Ann Pharmacother. 1996; 30: 1402-1407. PubMed
5. Krstenansky PM, Jones WN, Garewal HS. Effect of dicloxacillin sodium on the hypoprothrombinemic response to warfarin sodium. Clin Pharm. 1987; 6: 804-806. PubMed (Pubitemid 17153599)
6. Lacey CS. Interaction of dicloxacillin with warfarin. Ann Pharmacother. 2004; 38: 898. doi:10.1345/aph.1D484 PubMed
7. Kim KY, Frey RJ, Epplen K, Foruhari F. Interaction between warfarin and nafcillin: case report and review of the literature. Pharmacotherapy. 2007; 27: 1467-1470. doi:10.1592/phco.27.10.1467 PubMed (Pubitemid 47530454)
8. Shovick VA, Rihn TL. Decreased hypoprothrombinemic response to warfarin secondary to the warfarin-nafcillin interaction. DICP. 1991; 25: 598-600. PubMed
9. Qureshi GD, Reinders TP, Somori GJ, Evans HJ. Warfarin resistance with nafcillin therapy. Ann Intern Med. 1984; 100: 527-529. PubMed (Pubitemid 14126745)
10. Merwick A, Hannon N, Kelly PJ, O'Rourke K. Warfarin-flucloxacillin interaction presenting as cardioembolic ischemic stroke. Eur J Clin Pharmacol. 2010; 66: 643-644. doi:10.1007/s00228-010-0802-9 PubMed
11. Garg A, Mohammed M. Decreased INR response secondary to warfarin-flucloxacillin interaction. Ann Pharmacother. 2009; 43: 1374-1375. doi:10.1345/aph.1L676 PubMed
12. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005; 165: 1095-1106. doi:10.1001/archinte.165.10.1095 PubMed (Pubitemid 40720733)
13. Ibrahim OM, Allam A. Warfarin resistance in a patient with prosthetic valve endocarditis treated with cloxacillin. Saudi Pharm J. 1996; 4: 56-59. (Pubitemid 26101918)
14. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007; 41: 674-680. doi:10.1345/aph.1H423 PubMed (Pubitemid 46625492)
15. Conly J, Stein K. Reduction of vitamin K2 concentrations in human liver associated with the use of broad spectrum antimicrobials. Clin Invest Med. 1994; 17: 531-539. PubMed
16. Schentag JJ, Welage LS, Grasela TH, Adelman MH. Determinants of antibiotic-associated hypoprothrombinemia. Pharmacotherapy. 1987; 7: 80-86. PubMed (Pubitemid 17098186)
17. Bergeron MG, Brusch JL, Barza M, Weinstein L. Bactericidal activity and pharmacology of flucloxacillin. Am J Med Sci. 1976; 271: 13-20. doi:10.1097/00000441-197601000-00002 PubMed
18. Rolan PE. Plasma protein binding displacement interactions - why are they still regarded as clinically important? Br J Clin Pharmacol. 1994; 37: 125-128. PubMed (Pubitemid 24213753)
19. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002; 71: 115-121. doi:10.1067/mcp. 2002.121829 PubMed (Pubitemid 34271114)